UBS raised the firm’s price target on Syndax (SNDX) to $38 from $35 and keeps a Buy rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Strong Growth Potential and Market Expansion Justify Buy Rating for Syndax Pharmaceuticals
- Syndax Pharmaceuticals: Strategic Advancements and Growth Potential Reinforce Buy Rating
- Syndax price target raised to $22 from $19 at Barclays
- Syndax Pharmaceuticals Reports Strong Q3 2025 Growth
- Syndax reports Q3 EPS (70c), consensus (71c)